Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Healthcap in conjunction with investment in Cortendo AB (publ)
Mandate

Vinge advises Healthcap in conjunction with investment in Cortendo AB (publ)

November 03, 2014

Vinge has advised HealthCap VI L.P in connection with the execution of an investment agreement with Cortendo AB (publ) (“Cortendo”). The investment will be effected through a directed new issue of shares to HealthCap and other investors.

The new issue must be approved by a shareholders’ meeting of Cortendo and the meeting is expected to be held on or about 1 December 2014.Cortendo is a Swedish biopharmaceutical company which has its base in the United States.

Vinge’s team consisted of responsible partner Johan Winnerblad and associate Alex Miler.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025